Objective To evaluate efficacy and safety of botulinum toxin type B （BTX-B） in treatment of movement disorders including blepharospasm

oromandibular dystonia

hemifacial spasm

tremor

tics

and hypersecretory disorders such as sia-lorrhea and hyperhidrosis. Methods A retrospective study of BTX-B injections in treatment of 58 patients with various neurological disorders was performed. The mean follow-up time was 0.9 ± 0.8 years. Results of the first and last treatment of patients with at least 3 injection sessions were compared. Results The response of 58 patients to a total of 157 BTX-B treatment sessions was analyzed. Of the 157 treatment sessions

120 sessions （76.4%） resulted in moderate or marked improvement while 17 sessions （10.8%） had no response. The clinical benefits after BTX-B treatment lasted an average of 14 weeks. Of the 41 patients with at least 3 injection ses-sions （mean 10 ± 8.6）

most patients needed increased dosage upon the last session compared to the first session. Nineteen patients （32.8%） with 27 sessions （17.2%） reported adverse effects with BTX-B treatment. Conclusions Though most patients require increased dosage to maintain effective response after repeated injections

BTX-B is an effective and safe treatment drug for a variety of movement disorders

as well as drooling and hyperhidrosis.